Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population

Abstract

Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The objectives of this study were to determine the prevalence of atopic dermatitis in the population of the United States, the distribution of disease severity, and its impact on health-related quality of life. Among 1,278 participating adults, the prevalence (95% confidence interval) of atopic dermatitis was 7.3% (5.9e8.8). Overall, 60.1% (56.1e64.1) of participants were classified as having mild, 28.9% (25.3e32.7) as having moderate, and 11% as having severe (8.6e13.7) disease. Patients with atopic dermatitis and those with more severe disease had higher scores in the dermatology life quality index (mean [standard deviation] for AD patients ¼ 4.71 [6.44] vs. control individuals ¼ 0.97 [2.12]) (P < 0.001) and the hospital anxiety (mean [standard deviation] for AD patients ¼ 7.03 [4.80] vs. control individuals ¼ 4.73 [4.8]) and depression (mean, [standard deviation] for AD patients ¼ 5.83 [4.54] vs. control individuals ¼ 3.62 [3.61]) scales, indicating a worse impact on quality of life and an increased likelihood of anxiety or depression. Based on our prevalence estimates, 16.5 million adults would have a diagnosis of atopic dermatitis, with 6.6 million meeting criteria for moderate to severe disease. Our study confirms the high prevalence and disease burden of atopic dermatitis in this population.

Quantitative analysis of topical treatments in atopic dermatitis: unexpectedly low use of emollients and strong correlation of topical corticosteroid use both with depression and concurrent asthma

“…We found that the prevalence of patients requiring repeat antidepressant prescriptions is twice as high for patients with AD using high amounts of TCS vs. those who use low amounts of TCS (12% vs. 6%, Table ). These data confirm previously reported associations between AD and depression in adults and children and further validate the use of quantitative drug prescribing data to obtain clinically relevant ‘holistic’ treatment readouts. In this regard, perhaps the most obvious application of the approach presented herein will be the confirmation and quantification of the benefit of novel and often resource‐intensive treatments (e.g.…”

Depressive Symptoms and Sleep Disturbance in Female Nurses with Atopic Dermatitis: The Korea Nurses’ Health Study

“…The prevalence of adult AD varies widely from country to country, as it is 2.7-3.1% in Korea [3,4] and 7.3% in the United States [5]. AD has a significantly higher prevalence among females (9.3-10%) than males [5,6], and the Nurses' Health Study 2 (NHS2), which analyzed nurse health in the United States, reported that the prevalence of AD among female nurses was 10.1%, higher than that among all adults [7].…”

Estudio epidemiológico sobre dermatitis atópica en México

“…En México, a diferencia de otros, los médicos especialistas principalmente de alergia e inmunología clínica pueden atender tanto a población pediátrica como adultos, esto explica porque 62 % de los pacientes atendidos es mayor de 18 años, resultado que contrasta por lo publicado en la literatura, donde la prevalencia de DA es mayor en población pediátrica. 14,15,16 Existen diferentes criterios clínicos para el diagnóstico de DA; en México, el Consenso Mexicano para el Diagnóstico y Tratamiento de la Dermatitis Atópica en Niños y Adultos y las Guías CENETEC (Centro Nacional de Excelencia Tecnológica en Salud) recomiendan utilizar los criterios de Williams, por su sensibilidad y especifi cidad, además de su fácil aplicación (cuadro 1).…”